Personal profile
Research interests
Clinical trials of lipid-modifying diet and drug therapy. Outcomes studies involving lipid and metabolism modifying drugs. Particular interest in patients with inherited lipid disorders, such as familial hypercholesterolemia.
Clinical interests
Hypercholesterolemia, lipoprotein metabolism, combined hyperlipidemia, hyperlipidemia, lipid disorders, hypertriglyderidemia, cholesterol, triglycerides, HDL, LDL, cholesterol-lowering medications, lipid drugs, clinical trials.
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Navar, A. M., Nissen, S. E., Goldberg, A. C., Brunham, L. R., Wuerdeman, E., Neild, A. L., Kling, D., Hsieh, A., Butters, J., Ference, B. A., Laufs, U., Banach, M., Mehran, R. & Catapano, A. L. & 3 others, , Mar 2026, In: Nature medicine. 32, 3, p. 1052-1060 9 p.Research output: Contribution to journal › Article › peer-review
-
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
for the CORE-TIMI 72a and CORE2-TIMI 72b Investigators, Jan 29 2026, In: New England Journal of Medicine. 394, 5, p. 429-441 13 p.Research output: Contribution to journal › Article › peer-review
13 Link opens in a new tab Scopus citations -
Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association
Ahmad, Z., Agarwala, A., Cuchel, M., Barton Duell, P., Hegele, R. A., Hudgins, L., Jamison, A., Kalra, D., Khera, A., Knowles, J. W., Kullo, I. J., Morales, A., Rothstein, M. A., Saseen, J. J., Soffer, D. E., Warden, B. A., Weintraub, W. S., Williams, L. & Goldberg, A. C., 2026, (Accepted/In press) In: Journal of Clinical Lipidology.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
Sarraju, A., Brennan, D., Hayden, K., Stronczek, A., Goldberg, A. C., Michos, E. D., McGuire, D. K., Mason, D., Tercek, G., Nicholls, S. J., Kling, D., Neild, A. L., Kastelein, J., Davidson, M., Ditmarsch, M. & Nissen, S. E., May 17 2025, In: The Lancet. 405, 10491, p. 1757-1768 12 p.Research output: Contribution to journal › Article › peer-review
Open Access30 Link opens in a new tab Scopus citations -
Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia
PALISADE Study Group, Mar 11 2025, In: Circulation. 151, 10, p. 733-736 4 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Link opens in a new tab Scopus citations